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Metabolic syndrome (MetS) is a complex disorder characterized by coexistence of several
cardiometabolic (CM) factors, i.e. hyperlipidemia, obesity, high blood pressure and insulin
resistance. The presence of MetS is strongly associated with increased risk of cardiovascu-
lar disease (CVD). The syndrome was originally defined as an adult disorder, but MetS has
become increasingly recognized in children and adolescents.
Methods
Genetic variants influence biological components common to the CM factors that comprise
MetS. We investigated single locus associations between six single nucleotide polymor-
phisms (SNPs), previously shown to modulate lipid or sex hormone binding globulin
(SHBG) levels, with MetS in a Turkish pediatric cohort (37 cases, 323 controls).
Results
Logistic regression analysis revealed a significant association between rs1799941, located
in SHBG, and MetS (OR = 3.09, p-value = 0.006). The association with MetS remained after
sequential adjustment for each CM factor included in the syndrome definition, indicating
that the identified association is not being driven by any single trait. A relationship between
rs1799941 and SHBG levels, was also discovered, but it was dependent on MetS status. In
control subjects, the A allele of rs1799941 associated with a significant increase in SHBG
levels (p = 0.012), while in cases there was no association between rs1799941 and SHBG
levels (p = 0.963).
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Conclusions
The significant association between rs1799941 and MetS in children is not contingent on
any single CM trait. Additionally, the presence of MetS may abrogate effect of rs1799941
polymorphism on SHBG levels in children.
Introduction
Metabolic syndrome (MetS) is a complex condition defined by the clustering of 3 or more car-
diometabolic (CM) phenotypes, and is associated with increased cardiovascular disease (CVD)
morbidity and mortality [1–5]. MetS, which was originally described as an adult disorder [1–3],
has become increasingly recognized in children and adolescents [6]. Concurrent with the rising
trend in childhood obesity, MetS has increased in prevalence in the pediatric population world-
wide [7, 8]. Clustering of CM risk factors, in general, has also been shown to begin in youth [5].
Originally, MetS in children was defined as a direct consequence of childhood obesity [9].
However, CM risk traits such as high blood pressure and dyslipidemia are now common in
children even in the absence of obesity [10]. Furthermore, ethnic variations exist in the distri-
bution of CM risk traits in children [11]. In a previous study comparing children from Ankara,
Turkey to the Bogalusa Heart Study population, we reported that dyslipidemia and high blood
pressure were highly prevalent in children from Turkey even in the absence of obesity [12].
CM risk is also affected by sex hormone levels in children through regulation of lipids [13, 14].
Both sex hormone and sex hormone binding globulin (SHBG) levels are associated with lipid
levels and insulin resistance in children and adolescents [15].
Hormonal changes at puberty lead to increased fat mass, and decreased SHBG levels [16].
Circulating SHBG is the strongest known predictor of MetS in children and adolescents, with
lower SHBG levels associating with increased risk [15, 17]. Several studies present evidence of
genetic variants modulating lipid levels in adult populations [18–21]. In our pediatric cohort,
we previously showed that significant associations exist between SHBG (rs6257), CETP
(rs708272) polymorphisms and lipid traits (high triglycerides, low HDL-C and high LDL-C) in
children and adolescents [22]. Additionally, single nucleotide polymorphisms (SNPs) located
in the SHBG gene (rs1799941 and rs6257) have been associated with SHBG levels [23].
In our study, we investigated several SNPs from five genes known to associate with lipid or
circulating SHBG levels in adults (LPL, CETP, LIPC, ABCA1, and SHBG) for association with
MetS in a pediatric cohort [18–23]. We also evaluated genetic variants that associate with MetS
as a whole, thereby discovering underlying associations that impact only MetS, as opposed to
any single trait used to define it.
Methods
Study population and data collection
The study (n = 360) was derived from a cross sectional survey on the prevalence of cardiovas-
cular risk factors in a representative sample of school children in Istanbul, Turkey. Five differ-
ent state elementary and secondary schools were selected. Students who did not want to
participate in the survey were excluded (around 10% for elementary school children and 20%
for secondary school students). Blood samples were drawn at 9 am. The Institutional Review
Board of Marmara University and the Educational Board approved the study protocol. In-
formed consent was obtained from parents or guardians. Subjects were given case numbers
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and identities were kept confidential. At least one parent signed an informed consent
for participation.
Cardiometabolic risk variables and definitions
Anthropometry. Body mass index (BMI) was calculated as weight (kg)/height (m2). Using the
tables provided by the waist circumference percentiles in a nationally representative sample, we
determined subjects with increased waist circumference ( 90th percentile) [24]. Age- and sex-
specific cutoff points of BMI were also used to assess the overweight and obesity status [25].
Elevated blood pressure
Blood pressure was measured by automatic blood pressure monitor (Omron) 3 times while the
subjects were seated, and the last two measurements were averaged for analysis. Small and me-
dium-sized cuffs were used for arm circumferences of< 22 and 22–32 cm respectively. To find
the age specific height percentile level for each individual, we used the growth curves drawn for
healthy Turkish Children [26]. Using the tables provided by the Task Force Report on High
Blood Pressure in Children and Adolescents, we determined children and adolescents with ele-
vated blood pressure ( 95th percentile) [27].
Biochemical analysis
Patients were considered to be fasting if they reported at least 12 hours of fasting prior to blood
sampling. Complete lipid profiles were obtained, including total cholesterol (TC), high-density
lipoprotein cholesterol (HDL-C), triglyceride (TG), low-density lipoprotein (LDL-C) (calculated
with the Friedwald calculation: LDL = TC −HDL − [TG/5]). TG, HDL-C and glucose were mea-
sured by enzymatic colorimetric-assay method using Cobas Integra 800 kit (Roche Diagnostic).
Insulin and sex hormone binding globulin (SHBG) levels were measured by chemiluminescence
immunoassay method using Modular E170 kit (Roche Diagnostic). Analyses were performed in
an accredited laboratory (Centro Laboratorıes which are based in Istanbul / Turkey).
Hyperlipidemia and insulin resistance.A TG level 75th percentile or HDL-C level 25th
percentile were used to define high TG and low HDL, respectively [28]. Impaired fasting glucose
(IFG) was defined as 100 mg/dL [29]. Hyperinsulinemia was arbitrarily defined as fasting
value 18 μU/mL, a value considered indicative of insulin resistance in normoglycemic subjects
[30]. Homeostasis model assessment-estimated insulin resistance (HOMA-IR) was calculated
using the formula (glucose [mmol/L] x fasting insulin [μU/ml]/22.5) [31]. Insulin resistance is
defined based on a threshold of 3.16 [32].
Definitions of metabolic syndrome. Based on the adopted NCEP criteria [1], Subjects with
3 or more CM risk criteria were considered to have MetS. The risk criteria included: elevated
systolic and/or diastolic blood pressure ( 95th percentile), overweight or obesity status based
on an age- and sex-specific cutoff points of BMI, elevated TG, low HDL-C, and impaired fast-
ing glucose (IFG). WHO and IDF definitions of MetS were also used [2–4]. IFG or insulin re-
sistance (assessed by HOMA-IR) and waist circumference ( 90 percentile based on a
nationally representative sample) are the prerequisites for WHO and IDF definitions, respec-
tively. Additionally, both definitions require the presence of at least two other CM risk factors.
Subjects were assessed for all three definitions of MetS and children who fulfilled the criteria
for at least one definition were classified as having MetS in the current study.
Determination of the genotypes. Two ml of venous blood from subjects were collected
and stored at + 4°C prior to DNA isolation. The LPL stop codon polymorphism rs328 (S447Ter
(terminal codon), ABCA1 promoter polymorphism rs1800977 (C – 14T), LIPC promoter
polymorphism rs1800588 (C – 514T), and CETP promoter polymorphism rs708272 were
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analyzed—using restriction fragment length polymorphism (RFLP) after being amplified by po-
lymerase chain reactions (PCR). A base substitution from G (B1) to A (B2) in intron 1 of the
CETP gene leads to 3 genotypes, B1B1, B1B2 or B2B2 at Taq1B site (5454G>A). RFLP genotyp-
ing of the CETP polymorphism was carried out as previously described [33]. For SHBG poly-
morphisms, rs1799941 and rs6257, genotyping was performed by real time PCR amplification
and fluorescent probe melting point analysis on the Light Cycler 1.5 instrument (Roche Diag-
nostics GmbH, Mannheim, Germany) (S1 Table). For these PCR reactions, 50 ng genomic
DNA was amplified with the Light Cycler Fast Start DNAMaster HybProbe Kit (Roche Diag-
nostics GmbH, Mannheim, Germany). Each 20μl reaction contained 1X Fast Start DNAMaster
HybProbe, 1.5mMMgCl2, 0.3μM each primer and 0.15μM hybridization probe. After initial de-
naturation step at 95°C for 10 minutes, amplification was performed using 45 cycles of denatur-
ation at 95°C for 5s, annealing at 55°C for 20s and extension at 72°C for 20s. This was followed
by a melting curve analysis of 95°C for 0 s, 40°C for 30s and a slow ramp (0.1°C /second) to
85°C with continuous fluorescent acquisition.
Statistical Analyses. All marker genotypic distributions were assessed for deviations from
Hardy Weinberg Equilibrium (HWE) in the full dataset, and in cases and controls separately,
(S2 Table). HWE was tested using the software package PLINK [34]. A HWE p< 0.001 was
used to indicate significant deviation from equilibrium. Continuous and dichotomous demo-
graphic variables were assessed for significant differences between MetS cases and controls
prior to SNP genotype-phenotype analyses. For continuous variables the Shapiro-Wilkes test
was applied in order to determine if the variable was normally distributed. In instances where a
variable was not normally distributed (Shapiro Wilkes p< 0.05), and standard statistical tests
would be inappropriate, non-parametric analytical techniques were used. Unless otherwise in-
dicated, all statistical analyses in this study were performed, using the statistical package
STATA 11 [35].
Preliminary Association Testing. Logistic regression analysis was used to identify and
quantify associations between SNPs and MetS. Logistic regression models were adjusted for
age, gender, and circulating SHBG levels. Due to small sample size, dominant coding was used
for SNP genotype with the homozygous major genotype as the referent and the heterozygote
and homozygous minor genotypes were collapsed into one category (S3 Table). A nominal
p-value< 0.05 was used to signify a significant association and Bonferroni correction was ap-
plied to account for multiple testing.
Confirmation of the Integrity of Identified Association(s).Once a significant association
was revealed in preliminary analyses, we tested for the integrity of the genotype-phenotype re-
lationship by creating several independent adjusted models that included the nominally associ-
ated SNPs, covariates (age, gender, and circulating SHBG levels), and the six major defining
factors of MetS: low HDL-C, high TG, increased waist circumference, insulin resistance, obesi-
ty, and elevated blood pressure in a step-wise fashion. These additional models were compared
to the reference model that contained only SNP, age, gender, and circulating SHBG levels.
Each variable was dichotomized according to preset definitions prior to inclusion in the adjust-
ed analyses (S4 Table). Loss of significance in these models (p 0.05) was used to identify con-
founded associations between SNP(s) and MetS.
Assessment of the effect of SNPs in SHBG on circulating SHBG levels. Due to the non-
normality of circulating SHBG, we applied two complimentary non-parametric methods, the
Kruskal-Wallis (K-W), and the Non-Parametric (NP) Trend Test to investigate the difference
in SHBG levels as a function of SNP genotype. The K-W test is an alternative to the standard
Analysis of Variance (ANOVA) analysis and tests the null hypothesis of no difference in
SHBG levels between SNP genotype groups. For the NP Trend test, SNP genotypes were or-
dered by number of minor allele (0 = homozygous major, 1 = heterozygote, 2 = homozygous
SHBGGene Polymorphism Associates with Metabolic Syndrome in Children
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minor). Arranged in this manner, the NP Trend test assessed whether there was an increasing
trend in circulating SHBG levels for each additional copy of the minor allele. A p-value< 0.05
was used to determine significance of K-W and NP analyses.
In order to determine the direction of effect for significant associations identified from the
K-W and/or NP Trend tests, median regression was performed. To thoroughly explore the ef-
fect of SNP genotype on SHBG levels two separate SNP genotype coding schemes, additive
(coded 0, 1, or 2, depending on the number of minor alleles) and dominant (coded 0 or 1 in ref-
erence to the absence or presence of any minor allele), were implemented, in order to determine
if there was a difference of effect between case and control subjects. All median regression mod-
els were adjusted for age and gender, and significance threshold was set at p< 0.05. Visual rep-
resentations of the relationship between median or mean circulating SHBG and SNP genotype
were created, using version 2.11.3 of the gplots package, in the R statistical platform [36, 37].
Results
A subset of 360 Turkish children and adolescents (170 males, 190 females) was extracted from
a previously described cohort (n = 365) collected by Agirbasli et al [15]. All individuals with
available DNA samples from the original cohort were included in the present study. Demo-
graphics of all analyzed individuals are presented in Table 1.
Description of Single Nucleotide Polymorphisms
The chromosomal location, allele definitions, genotype distribution, and Hardy-Weinberg
equilibrium (HWE) measurements are presented in S1 and S2 Tables. No genotyped markers
deviated significantly from HWE in the full dataset, or in case/control subsets (all p> 0.001).
Dichotomous analysis of Metabolic Syndrome by genotype groups
A total of 37 subjects (11 males, 26 females) met at least one of the three established definitions
of MetS and were uniformly defined as MetS cases, regardless of the number of MetS defini-
tions (WHO, NCEP, IDF) that identified them (Table 2, S5 Table). The remaining 323
Table 1. Distribution of Demographics and Circulating Sex Hormone Binding Globin Levels in Metabolic Syndrome Cases and Controls.
Metabolic Syndrome Risk Factors Metabolic Syndrome Cases (n = 37) Controls (n = 323) P-Value
Gender1 29.7% 55.4% 0.003▪
Age2 12.2 (0.54) 13.1 (0.19) 0.020^
Family History of Cardiovascular Disease (CVD)3 [26(9)] [200(103)] 0.325
Family History of Hyperlipidemia (LPD)4 [29(6)] [212(90)] 0.116
Parental Smoking (PS)5 [14(23)] [133(190)] 0.696
Sex Hormone Binding Globin (SHBG)6 57.6 (7.16) 75.3 (2.38) 0.005^
Note: P-Values presented above are from the Chi-Square test of Association, unless otherwise indicated.
1 Percentage of indicated Metabolic Syndrome subset (i.e. cases or controls) that is female
2 Mean (Standard Error) of age measured in years
3 CM: [CVD Controls (CVD Cases)], CVD Case definition is presence of family history of Cardiovascular Disease
4 LPD: [LPD Controls (LPD Cases)], LPD Case definition is presence of family history of dyslipidemia
5 PS: [PS Cases (PS Controls)], PS Case definition is presence of either maternal or paternal smoking in the participant’s primary residence
6Mean (Standard Error) of Sex hormone binding globulin measured in nmol/l
▪P-value presented is from the two group test of proportions in STATA 11
^P-value presented is from Wilcoxon Rank Sum test
doi:10.1371/journal.pone.0116915.t001
SHBGGene Polymorphism Associates with Metabolic Syndrome in Children
PLOS ONE | DOI:10.1371/journal.pone.0116915 February 3, 2015 5 / 15
individuals in the study cohort were designated controls. Logistic regression analysis was per-
formed to identify significant associations between genotype and MetS for all analyzed SNPs
(Table 3). The models, dominantly coded, were adjusted for age, sex, and circulating SHBG lev-
els. Having at least one minor allele (A allele) at rs1799941, located in SHBG, associated with
increased odds of MetS (OR: 3.09, p = 0.006) and the effect remained after correction for multi-
ple testing (Table 3, S6–S7 Tables). None of the other analyzed markers associated with MetS.
Identification of genetic variants that associate with MetS, but not with any single factor,
supports the concept of MetS as a legitimate cohesive phenotype. Associations with MetS that
lose significance after accounting for the effect of a single factor would support the conclusion
that MetS is not a syndrome but merely the collection of unrelated independent traits. We
constructed a series of logistic regression models that sequentially adjusted for the inclusion
of single CM traits (S4 Table), and to assess effect on the association between rs1799941
and MetS (Table 4). The association between rs1799941 and MetS remained significant
Table 2. Metabolic Syndrome Case definition.
Metabolic Syndrome
Definition Source




Presence of at least THREE of the following: 33
1. Elevated diastolic or systolic blood pressure (> 95th
percentile)
2. Overweight or obese (BMI)
3. Elevated triglycerides (> 75th percentile)
4. Low HDL cholesterol (<25th percentile)
5. Elevated Glucose (> 100mg/dL)
World Health Organization
(WHO)
Impaired fasting glucose (glucose > 100mg) or Insulin
Resistance (HOMA-IR > 3.16) AND at least TWO of
the following:
9
1. Elevated blood pressure
2. Overweight or Obese (BMI)
3. Elevated triglycerides (>75th percentile)
4. Low HDL cholesterol (<25th percentile)
International Diabetes
Foundation (IDF)
Increased waist circumference ( 90th percentile;
ethnicity specific) AND at least TWO of the following
5
1. Raised triglycerides ( 150 mg/dl
2. Reduced HDL-cholesterol (40mg/dL for boys, 
50mg/dL for girls)
3. Raised blood pressure (systolic  130 mm Hg,
diastolic 85 mm Hg)
4. Elevated fasting glucose (>100 mg/dL)
Current Metabolic Syndrome
Study
Subjects that fulfill the criteria for at least ONE of the
three metabolic syndrome definitions: Adopted NCEP,
WHO, IDF
372
Note: Where applicable, above definitions show adjustments from adult thresholds to better fit a pediatric
cohort; for ethnicity specific thresholds, the Turkish population was used as a reference unless
otherwise indicated.
1Number of metabolic syndrome cases identified according to the specified definition; subjects may fulfill
the criteria for multiple definitions simultaneously.
2Number represents unique cases that fulfill the criteria presented by at least one of the following sources:
Adopted NCEP, WHO, or IDF. This is the number of cases used in the present study.
doi:10.1371/journal.pone.0116915.t002
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(2.67< ORs< 4.22; 0.003< p-values< 0.028) after adjustment for each CM factor included
in the MetS definition, confirming an association between rs1799941 and MetS.
Investigation of circulating SHBG as a possible association intermediary
Due to the genic location of rs1799941 in SHBG, we investigated whether circulating SHBG
modulates the SNP’s association with MetS. We employed non-parametric tests, Kruskal-Wallis
(K-W) and Non-Parametric Trend Test (NP), to determine whether a significant relationship
existed between rs1799941 and circulating SHBG levels. Our results demonstrated that circulat-
ing SHBG levels differed significantly by genotype (K-W p-value = 0.049), and furthermore,
that the minor allele correlated with an increase in SHBG levels (NP p-value = 0.031) (Table 5).
Table 3. Logistic regression results of Metabolic Syndrome Adjusted for known Metabolic Syndrome Risk Factors.
GENE SNP OR1 95% Confidence Interval P-Value
ABCA1 rs1800977 1.61 0.76–3.43 0.216
LPL rs328 0.92 0.36–2.32 0.859
CETP rs708272 0.67 0.31–1.45 0.312
LIPC rs1800588 1.01 0.47–2.16 0.988
SHBG rs1799941 3.09 1.38–6.91 0.006*
rs6257 0.93 0.43–1.97 0.841
Regression models above were adjusted for age, gender, and SHBG levels. Significant results are highlighted in bold.
Note: SNPs were coded coded dominantly for the effect of the minor allele (homozygous major = 0, heterozygote = 1, homozygous minor = 1). Odds
ratios presented above represent the change in odds per the addition of at least one copy of the minor allele for each analyzed SNP.
1: OR = Odds Ratio
*Effect remained significant after Bonferronni correction for multiple testing
doi:10.1371/journal.pone.0116915.t003
Table 4. Behavior of the association between rs1799941 and metabolic syndrome when the effects of single biological features defining
metabolic syndrome are held constant.
rs1799941 (SHBG)
Model Type1 Model Composition OR2 95% CI3 P-value4
Unadjusted rs1799941, age, gender, SHBG levels 3.09 1.38–6.91 0.006
Adjusted (High TG) rs1799941, age, gender, SHBG levels, High TG 3.10 1.13–8.52 0.028
Adjusted (Low HDLC) rs1799941, age, gender, SHBG levels, Low HDLC 4.22 1.48–12.04 0.007
Adjusted (Obese/Overweight) rs1799941, age, gender, SHBG levels, Obese/Overweight 3.80 1.47–9.83 0.006
Adjusted (Elevated BP) rs1799941k age, gender, SHBG levels, Elevated BP 3.69 1.57–8.67 0.003
Adjusted (Insulin Resistance) rs1799941, age, gender, SHBG levels, insulin resistance 2.89 1.28–6.54 0.011
Adjusted (Waist Circumference) rs1799941, age, gender, SHBG levels, Waist Circumference 2.67 1.09–6.49 0.031
Significant results are highlighed above in bold.
Note: rs1799941 was coded dominantly for the effect of the minor allele (homozygous major = 0, heterozygote = 1, homozygous minor = 1). Odds ratios
presented above represent the change in odds per the addition of at least one copy of the minor allele. All defining Metabolic syndrome criteria with
sufficient sample size (n5) were evaluated above.
1 Indicates the specific logisitic regression model tested: Unadjusted, or Adjusted (Possible Confounder included in model).
2 Indicates odds ratio (OR) for logisitc regression analysis between rs1799941 and metabolic syndrome in the specified model.
3 Indicates the 95% Confidence Interval associated with the presented odds ratio for each specified model.
4 Indates the p-value associated with the presented odds ratio for each specified model.
doi:10.1371/journal.pone.0116915.t004
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To determine the effect size of the association identified by K-W and NP analyses, we per-
formed median regression with rs1799941 genotype coded both additively and dominantly, ad-
justing for age and gender. Median regression results showed that for the additive model there
was an eight nmol/l increase (p = 0.016), while for the dominant model we observed a seven
nmol/l (p = 0.024) in median SHBG (Table 6, Fig. 1).
The minor allele of rs1799941 associated with both increased odds of MetS and increased
circulating SHBG levels. Since previous studies indicated that higher SHBG associated with a
decrease in risk of MetS [15], we assessed whether MetS status affected the relationship be-
tween rs1799941 and SHBG. Results from our MetS status stratified analyses showed that the
association with increased circulating SHBG levels in the full dataset was driven by control sub-
jects only (K-W p-value = 0.031, NP p-value = 0.012) (Table 7, Figs. 2–3). Because of the signif-
icant differences in the distributions of age and gender between MetS cases and controls
(Table 1, S8 Table), we performed explicit tests to evaluate the validity of the observed differ-
ence in median/mean SHBG seen between MetS cases and controls when we adjusted for the
effects of age and gender. Median regression analyses revealed that after accounting for the ef-
fects of age and gender, median SHBG levels were still significantly associated with MetS status
(p = 6.48E-09) (S9–10 Tables).
Table 5. Sex Hormone Binding Globulin Levels (SHBG) by rs1799941 genotype.
rs1799941 genotype groups Tests used to assess differences in SHBG
between genotype groups
SHBG GG AG AA K-W P-value1 NP Trend P-Value2
Median (IQR) 62.00 (36–101) 70.00 (41–110) 99.00 (70.5–153) 0.049 0.031
Mean (SE) 70.89(2.61) 77.88(4.674) 106.88(16.80)
Significant results are highlighted in bold.
Note: The above analyses were performed in the combined Full Cohort, without regard to Metabolic Syndrome status.
1P-value presented is for the Kruskal Wallis test for differences between groups
2P-value presented is from the Non-Parametric Trend test (increasing trend)
doi:10.1371/journal.pone.0116915.t005
Table 6. Regression Analysis of Sex Hormone Binding Globulin Levels by rs1799941 genotype.
Linear Median Regression
rs1799941 Genotype Coding * Coef.3a SE4 P-value 95% CI5
rs1799941_ADD1 8.00 3.30 0.016 1.50–14.50
rs1799941_DOM2 7.00 3.10 0.024 0.91–13.09
All regression models were adjusted for age and gender. Significant results are highlighted in bold.
*Describes the coding scheme used for rs1799941
1 rs1799941 genotype was coded dominantly with the minor allele as the reference: homozygous major = 0, heterozygote = 1, homozygous minor = 1
2 rs1799941 genotype was coded additively with the minor allele as reference: homozygous major = 0, heterozygote = 1, homozygous minor = 2
3a Regresssion coefficient that describes the change in median SHBG levels per the addition of one (rs1799941_ADD) or at least one (rs1799941_DOM)
minor allele at SNP rs1799941
4 Standard Error of regression coefficient
5 95% Confidence Interval for indicated regression coeficient
doi:10.1371/journal.pone.0116915.t006
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To quantify the newly observed relationship between rs1799941 genotype and circulating
SHBG levels, we performed median regression analyses, adjusting for age and gender (Table 8).
In controls, after accounting for the effects of age and gender, the significant association between
rs1799941 and SHBG levels remained (p-value = 0.021) (Table 8). In contrast, there was no evi-
dence of association between rs1799941 and circulating SHBG levels in cases (p-value = 0.332)
Fig 1. Median Circulating Sex Hormone Binding Globulin Levels vs. rs1799941 genotype (additive
coding). Fig. 1 presents the relationship between median SHBG levels and rs1799941 coded additively for
increasing numbers of the minor allele (A allele). Dashed line represents overall median SHBG level (65.0
nmol/l) in full cohort. Red circles represent denoted genotypic medians, and blue dotted lines with triangular
end bars represent the interquartile range for SHBG in the rs1799941 genotype subgroup indicated.
Connecting red lines illustrate trend in median SHBG by rs179941 genotype.
doi:10.1371/journal.pone.0116915.g001
Table 7. Sex Hormone Binding Globulin Levels (SHBG) by rs1799941 genotype in Metabolic Syndrome Cases and Controls.
rs1799941 genotype groups Non-Parametric Tests to assess
differences in SHBG levels between
genotype groups
SHBG GG AG AA K-W P-value1 NP Trend P-Value2
Controls Median [IQR] 62 [37–101] 71 [46–115] 99 [70.5–153] 0.031 0.012
Mean (SE) 72.18 (2.71) 81.48 (4.96) 106.88 (16.80)
Metabolic Syndrome Cases Median [IQR] 51 [22–74] 31 [22–108] NA 0.963 0.963
Mean (SE) 57.7 (9.17) 57.6 (11.91) NA
Significant results are highlighted in bold.
NA: There were no individuals in this genotype group
1P-value presented is for the Kruskal Wallis test for differences between groups
2P-value presented is from the Non-Parametric test for Increasing Trend in STATA 11
doi:10.1371/journal.pone.0116915.t007
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(Table 8). Although non-significant, the effect of the A allele in MetS cases trended in the oppo-
site direction compared to controls (Figs. 2–3, S1–S2 Figs., S6–S7 Tables). Overall, these results
suggest that the mechanism through which rs1799941 affects circulating SHBG levels is inhib-
ited or impaired in the presence of MetS.
Fig 2. Median Circulating Sex Hormone Binding Globulin Levels vs. rs1799941 genotype (dominant
coding). Fig. 2 presents the relationship between median SHBG levels and rs1799941 coded dominantly for
increasing numbers of the minor allele (A allele). Dashed line represents overall median SHBG level
(65.0 nmol/l) in full cohort. Red circles represent denoted genotypic medians, and blue dotted lines with
triangular end bars represent the interquartile range for SHBG in the rs1799941 genotype subgroup
indicated. Connecting red lines illustrate trend in median SHBG by rs179941 genotype.
doi:10.1371/journal.pone.0116915.g002
Fig 3. MetS status and the relationship between rs1799941 and SHBG. Fig. 3 assesses whether MetS
status affected the relationship between rs1799941 and SHBG. The association with increased circulating
SHBG levels in the full dataset was driven by control subjects only (K-W p-value = 0.031, NP p-value = 0.012).
doi:10.1371/journal.pone.0116915.g003
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Discussion
Our results indicate that rs1799941 associates significantly with MetS in children but not with
any defining CM trait. Additionally, the direction of the relationship between rs1799941 geno-
type and circulating SHBG levels differed significantly between subjects with and without
MetS. Two recently published studies using the same population provide strong evidence that
circulating SHBG is involved in the pathogenesis of MetS in children and adolescents [17, 38].
Low SHBG level was a significant predictor of insulin resistance, low HDL-C and MetS in chil-
dren [15, 38].
Genetic variation in SHBG affects the circulating sex hormone levels [23, 39]. Therefore, ge-
netic factors that lower SHBG levels may potentially affect MetS defining traits, including high
blood pressure, and obesity [40]. SHBG polymorphisms associate with insulin resistance [41, 42].
Previous studies report that the G allele of rs1799941 in SHBG associates with lower SHBG levels
[40–42]. We replicate these findings, but in control subjects only.
Our findings also support those from adult populations; lower levels of SHBG associate
with a higher risk of MetS as well as several CM risk components in postmenopausal women
[40–42]. Additionally, allele A of rs1799941 in SHBG associated with higher SHBG levels and
lower BMI, waist circumference, and systolic and diastolic blood pressure in postmenopausal
women [42]. SHBG polymorphisms are predictive of type 2 diabetes mellitus risk in the Physi-
cians Health Study [41]. In a study from Northern Spain both rs1799941 (A/G) and rs6257
(T/C) in SHBG showed significant associations with serum SHBG levels [43]. The G allele of
the rs1799941 and the T allele of rs6257 polymorphisms of SHBG gene associated with low
SHBG levels and CM risk in adult populations [42, 43]. Previous studies have shown that
SHBG levels vary by ethnicity and race in children, as does MetS [44]. For example, South
Asian children who had one parent with MetS presented with 24% lower SHBG as compared
to controls, and 55% less if both parents had MetS [45]. Hergenc et al report that Turkish mid-
dle-aged adults had similar total testosterone but lower SHBG levels compared with Germans
[46]. In the cross-sectional study, univariate analysis displayed that HDL-C had positive corre-
lations with SHBG in both sexes. Multivariate analysis demonstrated that most of the differ-
ences in HDL-C levels between Germans and Turks were explained by ethnicity,
Table 8. Regression Analysis of Sex Hormone Binding Globulin Levels by rs1799941 genotype in Metabolic Syndrome Cases and Controls.
rs1799941 Genotype Coding* Linear Median Regression
Coef.3 SE4 P-value 95% CI5
Controls rs1799941_ADD1 9.07 3.91 0.021 1.37–16.77
rs1799941_DOM2 13.00 4.89 0.008 3.37–22.62
Metabolic Syndrome Cases rs17999413# 14.00 14.23 0.332 -14.96–42.95
All regression models were adjusted for age and gender. Significant results are highlighted in bold.
*Describes the coding scheme used for rs1799941 1
1 rs1799941 genotype was coded dominantly with the minor allele as the reference: homozygous major = 0, heterozygote = 1, homozygous minor = 1
2 rs1799941 genotype was coded additively with the minor allele as reference: homozygous major = 0, heterozygote = 1, homozygous minor = 2
# There are no Metabolic Syndrome cases with the AA genotype; therefore, additive and dominant genotype coding in these individuals is identical
3 Regresssion coefficient that describes the change in median SHBG levels per the addition of one (rs1799941_ADD) or at least one (rs1799941_DOM)
minor allele at SNP rs1799941
4 Standard Error of regression coefficient
5 95% Confidence Interval for indicated regression coeficient
doi:10.1371/journal.pone.0116915.t008
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independently of obesity markers, insulin, and SHBG levels. Lower SHBG levels may help us to
understand the causes of CM risk in Turkish population [47].
Our results, demonstrating a significant association between rs1799941 and SHBG levels in
controls but not MetS cases, indicate a complex regulatory milieu. These results indicate that
the effects of the rs1799941 polymorphism are disease context dependent and may be affected
by the presence of one or more CM phenotypes. It should be noted that due to our small sam-
ple size, and the possibility that our detected effects are population-specific, these analyses will
need to be confirmed in a larger cohort and in several populations in order to demostrate the
validity of our findings. Previous studies have shown that SHBG levels, as MetS, vary by ethnic-
ity and race in children [45–47]. Therefore, these analyses will need to be repeated in several
populations in order to determine the generalizability of our results. The study was a cross sec-
tional survey of school students with several limitations. Environmental risk factors such as
diet or physical activity, which we did not measure in our study, can alter protein levels, there-
by modifying genetic effects. Despite these caveats, a robust genetic effect on susceptibility to
MetS was detectable. The mechanism(s) through which this variant operates is as yet unde-
fined, and is further complicated by the variable relationship between rs1799941 and SHBG
levels according to MetS phenotype. These results are suggestive of a complex regulatory sys-
tem that will require larger studies to assess the role of SHBG genotype on MetS in concert
with other genetic and environmental risk factors.
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